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THE ETIOLOGY OF ADHD 
 
STELLA SZETO 
ABSTRACT 
Attention Deficit/Hyperactivity Disorder (“ADHD”) is a complex multi-
factorial disorder that was first described in the late 1800s as a defect in 
moral control. By the early 1900s, ADHD shifted away from being a 
behavioral-based to a neurobiological-based disorder. During this period, 
individuals with ADHD were classified as having minimal brain damage. 
Early studies focused on the clinical presentation of ADHD. As advances 
in neuroimaging and molecular marker techniques started to develop, 
researchers were able to focus more on the neurobiological aspects of 
ADHD. This shift was instrumental to both the diagnosis and treatment 
of ADHD.  
 
This paper surveys the existing literature on ADHD in an attempt to 
elucidate its etiology. While several areas of research seem promising, so 
far, no single major contributor to ADHD has been identified. This paper 
first looks at the history behind ADHD. The historical background was 
instrumental in directing the course of ADHD research. Next, the 
Diagnostic and Statistical Manual of Mental Disorders (“DSM”) is 
examined with a focus on the changes made to DSM-IV and reflected in 
DSM-V. While DSM is a valuable diagnostic tool, its purpose in 
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elucidating the etiology behind ADHD is questionable. Despite that, 
discussion of the DSM is necessary as it is impossible to study a disorder 
without delineating the normal from the abnormal. What follows this 
discussion is a brief overview of comorbidities that are often associated, 
and possibly share, a common etiology with ADHD. The paper then 
examines the theories promulgated by researchers as to the 
neurobiological basis of ADHD. This examination is followed by a 
discussion of recent findings into the pathology behind ADHD, which 
mainly centers around differences in brain structure and connectivity. 
Further analysis of these studies reveals that sex plays an instrumental 
role in the type of brain abnormalities found in ADHD children. In 
addition, delays in brain development are analyzed, and age is discussed 
as a factor in the presentation of ADHD. This paper goes on to examine 
genetics as a contributor to the etiology of ADHD. This examination 
proves fruitful as several genes of interest seem to indicate a hereditary 
component of ADHD. Finally, treatment options such as psychosocial 
therapy and medications that help ADHD patients maintain a quality of 
life, are discussed. By studying the mechanism of action underlying 
these medications, additional clues as to the etiology of ADHD may be 
discovered. 
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There is still a long way to go before a complete picture of ADHD 
emerges. Already, studies are showing that race and environmental 
factors play a role in how ADHD presents. These two areas have rarely 
been studied and doing so will only serve to enhance the current 
understanding of ADHD. Despite an incomplete picture, the scientific 
community has come a long way from the 1800s where ADHD was 
thought to result from a defect in moral control. With early diagnosis and 
proper treatment, the ADHD individuals of today can live a life as close to 
that of their neurotypical peers as possible.   
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I. INTRODUCTION 
A BRIEF HISTORY OF ADHD 
ADHD as a Defect in Moral Control 
The first discovery of what would eventually become known as ADHD 
was made by Sir Alexander Crichton in 1798.1 Crichton was a Scottish 
physician who published a book called “An Inquiry into the Nature and 
Origin of the Derangement: Comprehending a Concise System of the 
Physiology and Pathology of the Human Mind and a History of the 
Passions and their Effects.” In the second chapter, titled “On Attention 
and its Diseases”, Crichton differentiated between normal and abnormal 
attention. Abnormal attention was described as “the incapacity of 
attending with a necessary degree of constancy to any one object.”2 
Crichton attributed this abnormality to “an unnatural or morbid 
sensitivity of the nerves” that the afflicted was either born with or 
acquired through some accidental disease.  
 
It was not until 1902 when Sir George Frederic Still published his lecture 
“On Some Abnormal Psychical Conditions in Children” 3 that the disorder 
took on a more scientific tone. Still described the disorder as a “defect of 
moral control”.3 This was further subdivided into two types: those that 
were accompanied by a “general impairment of intellect and physical 
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disease” 3 and those that were not. Patients in the former group were 
considered to have “brain damage” while those in the latter group were 
considered to have “disorders of attention”.3 
 
Still noted that this “lack of moral control may be shown in many ways” 3 
with the key being the need for “immediate gratification of self without 
regard…to the larger and more remote good of self.” 3 Still noted that 
many afflicted children had “a morbid failure to control…emotional 
activities”, had an “exaggeration of excitability”,3 and an “abnormal 
incapacity for sustained attention…without general impairment of 
intellect”. 3  
 
The next significant development would occur in 1932 when two German 
physicians by the names of Franz Kramer and Hans Pollnow described a 
“hyperkinetic disease of infancy” characterized by “marked motor 
restlessness”.4 Specifically, this motor restlessness lacked purpose and 
those with the disease would “indiscriminately touch or move everything 
available without pursuing a goal…[and] often do not use objects 
according to their function but regard them as stimuli inducing activity”. 
4 Kramer and Pollnow observed that the childhood hyperkinesis often 
decline in intensity by the age of seven4 but also recognized that “the 
disorder could have implications into adulthood”.5  
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In the 1940s, studies showed that children who sustained head injuries 
were later found to develop behavioral disorders.6 Six symptoms 
characterized this behavioral disorder: unpredictable variability in mood; 
hypermotility; impulsiveness; short attention span; fluctuant ability to 
recall matter previously learned; and conspicuous difficulty with 
arithmetic in school.7 The scientific community attributed these 
behaviors to the presence of “minimal brain damage” in the patient.8 
Based on this belief, hyperactivity alone was considered enough to 
diagnose a child with minimal brain damage.9 
 
This view persisted until the 1960s when Maurice Laufer noticed that 
there were children who presented with hyperkinetic symptoms but did 
not have a history of brain trauma or infections that would otherwise 
affect the central nervous system.10 Laufer suspected that the 
hyperkinetic symptoms were due to functional disturbances in the brain 
rather than brain damage. To test his theory, Laufer conducted an 
important study in which Metrazol was administered to children with 
and without the hyperkinetic syndrome. 10 The Electroencephalography 
(“EEG”) results showed that children with hyperkinetic syndrome had a 
lower clinical response threshold than children without the syndrome. 10 
However, when the same study was repeated using amphetamine, the 
EEG results showed no difference in clinical responsiveness between the 
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two groups. 10 These results supported Laufer’s theory. In 1963, the 
Oxford International Study Group of Child Neurology officially took the 
stance that “brain damage should not be inferred from problematic 
behavior signs alone” 11 and reclassified “minimal brain damage”11 as 
“minimal brain dysfunction”.11 During that same year, the National 
Institute of Neurological Diseases and Blindness assigned a national task 
force to further define what was considered “minimal brain 
dysfunction”.12 The task force decided that the term “minimal brain 
dysfunction” would apply to “children of near average, average, or above 
average general intelligence with certain learning or behavior disabilities 
ranging from mild to severe, which was associated with deviations of 
function of the central nervous system.”13 Most notably, the dysfunction 
would result in impairment of “perception, conceptualization, language, 
memory, and control of attention, impulse or motor function”. 13 
ADHD as a Hyperkinetic Reaction of Childhood 
In the 1980s, the term “minimal brain dysfunction” was criticized as 
being too general and the symptoms as being too heterogeneous. Instead, 
the disorder was further subdivided into more specific categories such as 
hyperactivity, learning disability, dyslexia, and language disorders.14 
Despite the behavioral component of ADHD, the scientific community 
continued to view ADHD as a biological disorder rather than a behavioral 
  5 
one. 
 
In 1968, DSM-II was published and included the disorder under the title 
“Hyperkinetic Reactions of Childhood”.15 This disorder was defined as 
being “characterized by overactivity, restlessness, distractibility, and 
short attention span, especially in young children; the behavior usually 
diminishes by adolescence”. 15 
 
It was not until the 1970s that the terms Attention Deficit Disorder 
(“ADD”) and ADHD were officially coined. During this period, physicians 
shifted their focus away from the hyperactive to the inattentive 
component of ADHD. This shift in focus is attributable to Virginia 
Douglas, who, in a paper addressed to the Canadian Psychological 
Association, concluded that deficits in attention and impulse control 
played a more important role than hyperactivity in ADHD.16 Douglas also 
noted that stimulant medications were effective in relieving symptoms of 
inattention. 16 Due to Douglas’ influential paper, the American 
Psychiatric Association (“APA”) decided to replace the term “Hyperkinetic 
Reaction of Childhood” with the term “Attention Deficit Disorder with or 
without Hyperactivity” in DSM-III.17 In doing so, the APA eliminated the 
need for hyperactivity to be present before an ADHD diagnosis could be 
made. 
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In DSM-III, the disorder was further subdivided into three types: 
inattention, impulsivity, and hyperactivity, each with its list of 
symptoms. The subtypes were eventually eliminated in DSM-III-TR in 
favor of a single combined list. 17 Subsequently, the disorder was 
renamed “Attention Deficit-Hyperactivity Disorder” to reflect this 
change.18 
 
ADHD as a Heterogeneous and Dimensional Disorder 
In the 1990s, technological advances in neuroimaging began to shed new 
light on ADHD. Researchers were able to show that structural brain 
abnormalities existed in children with ADHD.14 In addition, it was 
discovered that genetics may also play a role in the disorder.19 Based on 
several large studies, which showed that ADHD symptoms were indeed 
heterogeneous, the APA reintroduced the three ADHD subtypes of 
inattention, hyperactivity-impulsivity, and combined, back into DSM-
IV.20 Research also showed that “ADHD was not exclusively a childhood 
disorder, which disappeared with age as was previously thought, but 
rather a chronic persistent disorder remaining into adulthood in many 
cases”.14 To reflect this new understanding of ADHD, DSM-IV included 
“workplace difficulties” as one possible symptom of the disorder.20 
Although DSM-IV-TR was eventually published in 2000, the changes 
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were limited to the descriptive text while the core definition of ADHD 
remained the same.1 
 
In 2013, the APA published DSM-V.21 Most notably, the ADHD subtypes 
and diagnostic symptoms remained mostly unchanged from those in 
DSM-IV. This suggests that the criteria used to diagnose ADHD in DSM-
IV was, to an extent, effective.22 Despite many shared similarities, there 
are still significant differences between the two editions. These differences 
reflect the advances made in ADHD research and will be discussed in 
Section II below. 
 
II. DIAGNOSING ADHD 
DSM-V DIAGNOSTIC CRITERIA 
To capture the multi-faceted nature of ADHD, organizations such as the 
APA, International Classification of Diseases (“ICD”), and World Health 
Organization (“WHO”) each published their own ADHD diagnostic 
manual. Currently, DSM-V is the most commonly used diagnostic tool in 
the medical profession.22 While the use of DSM-V in discerning the 
etiology of ADHD is questionable, nevertheless, it still plays an important 
role. Without accurately delineating the normal from the abnormal, any 
efforts to discover the etiology behind ADHD would be futile.  
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Under DSM-V, an individual can be diagnosed with ADHD if the following 
criteria are met as shown in Figure 1 below.21 
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Figure 1. ADHD Diagnostic Criteria Under DSM-V21 
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A COMPARISON: DIFFERENCES BETWEEN DSM-IV-TR AND DSM-V 
While the core definition of ADHD in DSM-V remains mostly unchanged 
from that in DSM-IV, other significant changes were made to reflect the 
current understanding of ADHD. These changes are highlighted in Table 
1 below. 
 
 
  
Table 1. ADHD Diagnostic Criteria: A Comparison Between DSM-IV-TR and DSM-V23 
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Age of Onset 
In DSM-V, the APA departed from its former position that symptoms of 
ADHD must appear before the age of 723 before a diagnosis of ADHD 
would be considered. The APA opted for a more lenient approach and 
extended the threshold to age 12. 21 This change was supported by 
research, which showed that ADHD patients often do not experience 
noticeable impairments until later in life when expectations for self-
management appears.22 In addition, ADHD patients that were not 
diagnosed until later in life often do not recall when their symptoms first 
appeared. 22 In one study, adults with ADHD were asked to recall when 
their symptoms of ADHD first appeared. When the threshold for recalling 
the age of onset was extended from 7 to 12, the rate of recall increased 
from 50% to 95%.24 This result is unsurprising since ADHD individuals 
often have difficulty recalling details. By extending the age of onset to 12, 
the risk that an individual with ADHD will go by undiagnosed will be 
significantly reduced. Concerns have been raised about how these 
changes may affect the number of people diagnosed with ADHD. 
However, studies found that these changes only resulted in a 0.1% to 
3.55% increase in ADHD prevalence.25 Other concerns include clinicians 
misattributing normal adolescent behaviors to symptoms of ADHD.23 
Despite these concerns, studies show that the change made in DSM-V 
offers a good working balance between the need for specificity and 
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sensitivity.26 As discussed in Section III below, an early diagnosis is 
paramount to maintaining the quality of life of individuals with ADHD 
since the effects of the disorder extend well past their childhood years. 
Number of Symptoms 
In DSM-IV, six or more symptoms were required before a diagnosis of 
ADHD could be made.20 Since then research has shown that this 
requirement is only suitable for young children. For late adolescence and 
adults, a lower threshold should be used.27 In DSM-V, APA adopted this 
view and lowered the threshold to five or more symptoms for patients age 
17 and older.21 For the first time in history, APA explicitly acknowledged 
that ADHD could present de novo outside of childhood. Critics voiced 
concern that lowering the threshold would lead clinicians to over-
diagnose ADHD.28 While a lower threshold may increase the prevalence 
of ADHD, this increase is most likely attributed to patients who were 
formerly undiagnosed under DSM-IV rather than a sudden increase in 
clinician over-diagnosis.  
Presentation of Symptoms 
The term “subtypes”20 in DSM-IV was replaced by the term 
“presentations”21 in DSM-V. While “subtype” connotates a stable trait, 
“presentation” more accurately reflects the heterogeneous and 
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dimensional nature of ADHD symptoms.22 The heterogeneity of these 
symptoms is commonly seen in boys with ADHD who often display signs 
of hyperactivity and impulsivity in their childhood years. However, upon 
reaching adulthood, most of these hyperactive symptoms have largely 
disappeared, leaving inattention as the only trace of ADHD.  
Elimination of Clinical Impairment 
In another departure from DSM-IV, the APA eliminated the need for 
ADHD symptoms to be “impairing” 20 and found that the presence of 
“symptoms alone” 21 would suffice. This change in terminology serves to 
increase the reliability of DSM-V as a diagnostic tool. “Symptoms” are 
more readily observable and quantifiable than “impairments”, which 
depend heavily on patient subjectivity. Since not every individual 
experiencing ADHD symptoms will experience an impairment, this 
change makes DSM-V more inclusive than any of its predecessor.  
Symptom Interference with Patient Life 
The APA also removed another subjective element from DSM-V when the 
need for symptoms to be “clinically significant” 20 was discarded. Instead 
of asking clinicians to decide whether the symptoms meet the threshold 
for clinical significance, DSM-V took a broader approach requiring only 
that the “symptoms interfere with or reduce the quality of social, 
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academic, or occupational functioning”. 21 
New Sections in DSM-V 
In addition to the changes mentioned above, the APA added two sections 
to DSM-V. 
Severity 
DSM-V outlined three levels of ADHD severity: mild, moderate, and 
severe. 21 Although the qualitative descriptions of each level could be 
more specific, nonetheless, by including severity as part of DSM-V, the 
APA took the first step in acknowledging ADHD as a spectrum disorder.  
Partial Remission  
Another section new to DSM-V was “Partial Remission”. 21 In previous 
DSM editions, an individual could either only have or not have ADHD. In 
DSM-V, the APA acknowledged that since ADHD is a spectrum disorder, 
partial remission can occur. Unlike a regular ADHD diagnosis, however, 
the criteria for “ADHD in Partial Remission” 21 is stricter. To qualify for an 
“In Partial Remission Diagnosis”, 21 DSM-V requires that the symptoms 
“results in impairment” 21 rather than simply “interferes with or reduces 
the quality of [the patient’s] social, academic, or occupational 
functioning”. 21 In this regards, DSM-V retains the older terminology 
found in DSM-IV. 
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EFFECT OF CHANGES IN DSM-V 
The changes made in DSM-V are mostly positive. Importantly, the APA 
recognized that ADHD is a chronic disorder that extends well past 
childhood. This recognition was attributed to findings in follow-up 
studies, which show that approximately 50% of children with ADHD 
continue to suffer from symptoms of ADHD as adults.29 In addition, the 
APA recognized that ADHD is a disorder with different levels of severity 
as well as forms of presentation that vary over the lifespan of the 
individual.30 Longitudinal studies showed that ADHD individuals with 
predominantly hyperactivity-impulsivity symptoms tend to shift towards 
predominantly inattentive symptoms with increasing age.29 
 
Unlike its predecessor, DSM-V is a less rigid and more inclusive 
diagnostic tool that acknowledges the fluidity of the disorder. As a result, 
patients who did not fall neatly into any of the categories outlined under 
DSM-IV can now be diagnosed and seek the necessary help. The 
increased rate of diagnosis under DSM-V can be attributable to an 
increase in sensitivity of the test, resulting in less false negatives. In a 
16-year follow-up prospective study, clinicians were only able to diagnose 
28% of the 176 adults as having ADHD under DSM-IV, even though all 
176 adults had a well-characterized history of ADHD.31 The failure to 
diagnose was mostly due to difficulties the subjects had in recalling 
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symptoms of ADHD before the age of 7, a threshold requirement for 
ADHD diagnosis under DSM-IV.31 Given the lifetime severity of having 
ADHD,30 it is crucial that a missed diagnosis of ADHD diagnosis not 
occur. The changes made in DSM-V will help alleviate some of this 
burden as its diagnostic criteria balances both the need for sensitivity 
and specificity. 
OTHER SCREENING METHODS FOR ADHD 
Although DSM is the most commonly used standard for diagnosing 
ADHD in the medical community, other diagnostic tests and follow-up 
scales for ADHD also exist. Some of these include the ADHD Symptom 
Checklist, SNAP-IV Teacher and Parent Rating Scale, Connors Rating 
Scales (Revised), Brown Attention Deficit Disorder Scales for Children, 
and the ADHD Symptoms Rating Scales.32 For an accurate ADHD 
diagnosis to occur, there must also be an in-depth patient interview in 
addition to the use of the above tests. 
 
For adults, additional tests used to diagnose ADHD include: Adult Self 
Report Scale, Connors Adult ADHD Scales, Brown Attention Scales, and 
the Adult ADHD Self-Report Scale published by the WHO.32 Of the 
several tests listed, the one by WHO is more commonly used as an initial 
screening tool.6 This is in part due to the simplicity and brevity of the test 
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as shown in Table 2 below. 
 
Table 2. WHO Screening Test for Adults with ADHD6 
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III. COMORBIDITIES  
In addition to problems with attention, individuals with ADHD also have 
a higher rate of comorbidities, such as psychiatric disorders and 
substance abuse disorders than their neurotypical cohort.30 ADHD 
patients also suffer from a lower quality of life that extends well past 
their childhood years. Thus, ADHD is much more than just an attention 
disorder. The global impact ADHD has on patient lives highlights the 
importance of an early ADHD diagnosis. The earlier patients receive 
treatment, the better chance they have of staving off the adverse effects 
ADHD have on their quality of life. 
Depression and Anxiety 
Individuals with ADHD have a two-fold higher risk of having depression 
as compared to their non-ADHD peers. 33 The co-occurrence rate of 
ADHD with Major Depressive Disorder is up to 50% in adults.34 
Neuroimaging studies show that the reduction in hippocampus volume 
commonly seen in patients with Major Depressive Disorder,35 is also 
present in patients with ADHD.36 This suggests that the abnormalities 
underlying both disorders share a common origin. Finally, symptoms of 
anxiety, such as restlessness and distractibility, may often be mistaken 
for ADHD. As a result, individuals with ADHD often go through life with 
undiagnosed anxiety.37 
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Substance Abuse Disorder 
Data shows that children with ADHD are at an increased risk of 
substance abuse.38 They are also twice as likely to become addicted to 
cigarettes than non-ADHD children.6 Cigarettes are also known to 
increase the risk of drug and alcohol use, adding yet another layer of 
complexity to the disorder.38 In addition, a disproportionate number of 
ADHD individuals suffer from substance abuse with the abuse being 
more severe and longer in duration than those without ADHD.39 The 
effects of these comorbidities extend well past the childhood years 
leading ADHD patients towards a life of academic underachievement, 
lower income, unstable employment, and unfulfilling relationships.40 
IV. THEORIES ON THE ORIGIN OF ADHD 
Since the late 1900s, six influential theories on ADHD have emerged. 
Each of these theories builds upon their predecessors to elucidate the 
etiology and pathology behind the disorder.  
Executive Function Theory  
In 1997, Russell Barkley proposed that the impulsivity associated with 
ADHD stemmed from the inhibitory control centers of the brain.41 
According to Barkley, a primary deficit in inhibition control mainly 
affected four areas of executive functions: working memory, self-
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regulation, speech internalization, and behavioral reconstruction.41 It is 
these executive function deficits, Barkley suggested, that are responsible 
for producing the symptoms of motor control commonly seen in ADHD 
individuals.41 
Frontostriatal Theory  
Additional research showed that, while deficits in inhibitory control may 
contribute to ADHD symptoms, this does not account for the wide range 
of functional problems observed in ADHD patients.2 Adding to Barkley’s 
theory, Kenneth Heilman proposed that, because the striatum influences 
both response execution and inhibition, deficits in the frontostriatal 
region of the brain also contributes to the lack of executive control 
commonly seen ADHD patients.42  
Cognitive-Energetic Theory 
Joseph Sergeant recognized that there was a dynamic interplay between 
two systems in the brain, the tonic system, and the phasic activation 
system.43 Sergeant proposed that a relationship existed between the 
“bottom-up energetic system”,2 which required activation and the “top-
down cognitive system”,2 which inhibits the energetic system by exerting 
executive control.43 Unlike Barkley’s executive function theory, Sergeant’s 
theory recognizes the subcortex as a region that can directly modify 
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outputs of executive function.2 As a result, under Sergeant’s theory, 
deficits in the subcortex can directly contribute to symptoms of ADHD. 
Motivation and Delay Aversion Theory 
The motivation and delay aversion theory is centered around two 
circuitries.44 The first circuitry is the dorsal-frontostriatal circuit, which 
is involved in inhibition.44 The second circuitry is the ventral-
frontostriatal circuit, which is involved in rewards.44 Deficits in these 
circuitries result in the delay aversion experienced by ADHD individuals 
as well as decreased sensitivity to reward.45 
The motivation and delay aversion theory has expanded to include the 
presence of a third pathway, whose deficit may be responsible for some of 
the symptoms of ADHD. Abnormalities in cerebellar functioning leads to 
deficits in time discrimination and motor synchronization difficulties 
seen in ADHD patients.46 
Response Variability Theory  
ADHD patients have slower processing speed that manifests as a longer 
mean response time.2 Researchers believe that this is due to 
abnormalities in the response-time distribution curve in ADHD patients.2 
Under the response variability theory, the longer mean response time 
seen in ADHD patients is due to a lag in motor activation.2 This lag can 
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be overcome by introducing an unpredictable stimulus to “jolt” the 
internal response of ADHD patients.2 
Sluggish Cognitive Tempo Theory 
Under the sluggish cognitive tempo theory, patients with ADHD 
experience three main symptoms: lethargy, underactivity, and slowness.2 
These symptoms are distinct from the inattentive-type symptoms and are 
thought to be attributed to abnormalities in the selective attention 
processes of ADHD patients.2 While the APA considered adopting a 
similar concept in DSM-V using the term “Restrictive Inattentive 
Presentation”, it was ultimately not included.2 
 
While there are many theories as to the etiology and pathology of ADHD, 
these theories are not mutually exclusive. Together, these theories 
illustrate how different regions of the brain contribute to, and in some 
instances amplify, the symptoms of ADHD.  
V. PATHOLOGY 
Recent advances in neuroimaging play an essential role in ADHD 
research. Using imaged-based methodologies, scientists were able to find 
several neurobiological differences between individuals with ADHD and 
their neurotypical peers. These differences can be attributed to structural 
changes and distinct connectivity patterns unique to ADHD patients. 
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Together, these finding may help further explain the etiology and 
pathology behind ADHD. 
AN OVERVIEW OF NEUROIMAGING TECHNIQUES  
A brief overview of the commonly used neuroimaging techniques 
discussed in this section is presented below. 
General Imaging 
Magnetic Resonance Imaging (“MRI”): Non-invasive technique that 
utilizes the magnetic waves given off by tissues to generate an image. 47 
Gray Matter Imaging 
Structural MRI (“sMRI”): Non-invasive magnetic resonance imaging 
modality used to map gray matter structures in the brain.47  The spatial 
distribution between different regions of the brain are also preserved.47 
 
Voxel Based Morphometry (“VBM”): Non-invasive imaging modality used 
to measure the volume of gray matter structures within the brain.47 
White Matter Imaging 
Diffusor Tensor Imaging (“DTI”): Non-invasive magnetic resonance 
imaging modality used to map white matter connections within the brain. 
48 This is done by measuring the motion of diffusion in water molecules. 
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48 The direction of diffusion is quantified using a calculated value known 
as Fractional Anisotropy. 48 Increased fractional anisotropy is negatively 
correlated with white matter connectivity.48 
 
Resting-State Functional Connectivity (“rs-fMRI”): Non-invasive imaging 
technique that maps white matter connections in a brain at rest.47 
 
Functional MRI (“fMRI”): Non-invasive imaging technique that looks at 
white matter connections within the brain while the brain is engaged in 
an assigned task. 47 
 
Functional Near-Infrared Spectroscopy (“fNIRS”): Non-invasive imaging 
technique that looks at white matter connections within the brain while 
the brain is engaged in an assigned task. 47  
 
A Comparison of fMRI and fNIRS: Both fMRI and fNIRS measure white 
matter connectivity of the brain while the brain is engaged in an assigned 
task. However, while fMRI uses the magnetic waves given off by tissues 
to measure white matter connectivity, fNIRS uses hemodynamic changes 
and hemoglobin oxygenation levels to do the same. 47 fNIRS is less 
sensitive than fMRI and with a maximum penetration of up to 3cm 
within the scalp. 47 However, fNIRS has the advantage of using emitters 
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and detectors as its source of technology. 47 Because emitters and 
detectors are highly mobile and can be placed inside caps, researchers 
can study changes to white matter connectivity in real-time as subjects 
interact with the environment. 47  
Microstructural Imaging  
Positron Emission Tomography (“PET”) and Single Photon Emission 
Computed Tomography (“SPECT”): Measures the positron or gamma rays 
emitted by a decaying radionuclide.47 This imaging technique is often 
used to study microstructural changes within the brain such as receptor 
binding potentials, neurotransmitter turnover, and cerebral perfusion.  
GRAY MATTER DIFFERENCES 
Through neuroimaging techniques, researchers noticed several key 
structural gray matter differences in ADHD patients. These differences 
mainly centered around the density and volume of several gray matter 
regions of interest as well as the cortex. Since the cortex plays an 
important role in brain maturation, researchers suspected that any 
abnormalities affecting the cortex may contribute to ADHD. 
Structural Differences 
Meta-analysis of several sMRI studies shows that the brain volume and 
gray matter composition of ADHD individuals are 3% to 5% lower than 
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those without ADHD.49 Structural abnormalities found in the gray matter 
of ADHD individuals are highly driven by sex and age. The impact these 
characteristics have on the symptoms and presentations of ADHD will be 
further discussed in Section V and VI. 
Volume Differences 
Using VBM, one study showed that ADHD patients had decreased gray 
matter in the ventrolateral prefrontal and insular-striatal regions of the 
brain, including the right insula, putamen, globus pallidus, and caudate 
nucleus.50 Another study showed that ADHD patients have significantly 
smaller gray matter volume in the pre-central gyrus, medial cortex, 
orbital frontal cortex, cingulate cortex, and para-cingulate cortex than 
their healthy peers.51 Interestingly, their unaffected first-degree relatives 
have a moderate amount of gray matter reduction in the same regions as 
well.51 This finding suggests that reductions in gray matter volume may 
be genetically driven.51 The role genetics play in ADHD will be further 
discussed in Section VII. 
WHITE MATTER DIFFERENCES 
In addition to the changes found in gray matter, researchers discovered 
that ADHD also affects white matter fiber bundles in the brain.47 Using 
DTI, researchers found that the structural integrity of white matter tracts 
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sub-serving the frontostriatal-cerebellar neurocircuitry were disturbed in 
patients with ADHD, with the most common one being the corpus 
collosum.52 Functional connectivity abnormalities in white matter tracts 
can be divided into two groups: resting-state functional connectivity and 
task-based functional connectivity.  
Resting-State Functional Connectivity 
Researchers used rs-fMRI to look at the relationship between different 
neural activities in the brain.47 Specifically, the focus was on regions of 
the brain that were responsible for motivation such as the default-mode 
network, cognitive control network, and cortico-striato-thalamo-cortical 
loops.53 These neural circuitries are thought to be implicated in ADHD.53 
The results showed that ADHD patients had decreased functional 
connectivity within the default mode network, between the default mode 
network and cognitive control network, and between the cognitive control 
network and cortico-striato-thalamo-cortical loops compared to healthy 
controls.53 This study is in line with the inattention, timing difficulties, 
and delay aversion characteristics often seen in ADHD patients. 
 
A similar study found that functional connectivity within the executive 
control and the cerebellum network was stronger in adults with ADHD 
than in healthy adults.54 Analysis of these results revealed a positive 
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correlation between the strength of connection within these regions and 
the severity of hyperactivity-impulsivity symptoms exhibited by ADHD 
patients. 
 
These results are consistent with previous studies, which showed that 
abnormal connections within the frontal-striatal-cerebellar network led 
to difficulties with timing, inhibition, impulsivity, and reward.55 Another 
study showed that reduced connectivity in the fronto-parietal network 
led to issues with working memory, attention, and cognitive control.56 
Together, these studies suggest that the etiology of ADHD can in part be 
attributed to a brain-wide neural dysfunction. 
Anterior Cingulate Cortex and Cerebellum 
One study used rs-fMRI to examine six networks of interest in an 
attempt to elucidate the role resting-state functional connectivity has in 
ADHD.54 The six networks of interest along with the corresponding 
regions of the brain activated are shown below in Figure 2. 
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Figure 2. rs-fMRI of Six Networks of Interest and the Corresponding Regions of Brain 
Activated54 
 
ADHD patients and healthy controls underwent rs-fMRI. A comparison of 
the results revealed that the ADHD group exhibited a stronger resting-
state functional connectivity within the executive control network located 
in the anterior cingulate cortex and the cerebellum network than the 
control group. Further analysis showed that the strength of these 
connections was positively correlated with symptoms of hyperactivity-
impulsivity in ADHD.54 The results of this study are shown below in 
Figure 3 and Figure 4. 
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Figure 3. Positive Correlation Between the Strength of Connectivity in the 
Executive Control Network and ADHD Status (Top); Positive Correlation Between 
the Strength of Connectivity in the Cerebellum Network and ADHD Status 
(Bottom).54 
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Figure 4. Positive Correlation Between the Strength of Connectivity in the 
Executive Control Network and Symptoms of Hyperactivity-Impulsivity (Top); 
Positive Correlation Between the Strength of Connectivity in the Cerebellum 
Network and Symptoms of Hyperactivity-Impulsivity (Bottom).54  
 
The executive network has been described as a “transitional network 
linking cognition with emotion and interception.”57 It is unsurprising, 
therefore that abnormalities found within the executive control network 
correspond to symptoms of ADHD. Since the anterior cingulate cortex 
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and prefrontal cortex are involved in inhibitory control, abnormalities in 
either region may result in decreased inhibitory control and therefore an 
increase in hyperactivity-impulsivity symptoms.58 
Default Mode Network  
Resting-state functional connectivity abnormalities are also found in the 
default mode network of ADHD patients. Within the default mode 
network, ADHD patients show a higher level of activation during rest and 
a higher level of deactivation during task performance.59 These changes 
may be responsible for the response variability and attention deficiencies 
commonly seen in ADHD patients.60 Additional studies found that 
resting-state functional connectivity in adults with persistent ADHD was 
often: 
• Reduced within the default mode network;61 
• Abnormal62 (Sato 2012) and less negative61 between the default 
mode network and dorsal anterior cingulate; and 
• Stronger between the default mode network and dorsolateral 
prefrontal cortex.63  
Attention Network and Affective Cognitive Control Network  
Resting-state functional connectivity differences were also found in the 
attention and the affective cognitive control networks. Specifically, 
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resting-state functional connectivity in adults with persistent ADHD was 
often found to be: 
• Decreased within the dorsal/ventral attention networks;64 and 
• Increased within the affective network and lateralized cognitive 
control network.64 
Changes in resting-state functional connectivity is so prominent in the 
brains of ADHD individuals that researchers were able to distinguish 
ADHD patients from the control group based on rs-fMRI alone.65 The 
most prominent clues were due to regional homogeneity differences in 
the anterior cingulate cortex, cerebellum, insula, and basal ganglia.65 
Task-Based Functional Connectivity 
In addition to assessing differences in resting-state functional 
connectivity, researchers also looked at differences in functional 
connectivity of ADHD patients during task-based activities. In one study, 
subjects were given a stop-signal task during an fMRI study. The results 
showed that there were differences in hemodynamic patterns between 
the two groups. (P118) Another fMRI study showed that the fronto-
striatal, fronto-parietal, and ventral regions of the brain responsible for 
attention is under-activated in ADHD patients.66 The fronto-parietal 
network is important in goal-orienting executive processes while the 
ventral network is important in orienting attention towards salient 
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external stimuli. Under activation of these areas may contribute to the 
inattentiveness commonly seen in patients with ADHD.47  
Attention Network and Inhibitory Network 
A meta-analysis of fMRI studies revealed that ADHD patients 
consistently experience functional abnormalities in the attention and 
inhibition networks located in the fronto-basal ganglia. Abnormalities 
within the attention network are mainly found in the dorsolateral 
prefrontal cortex, parietal region, and cerebellar region.67 Abnormalities 
within the inhibition network are mainly found in the inferior frontal 
cortex, anterior cingulate cortex, and supplementary motor areas.67 
Reward Network  
Studies looking at the reward network found that ADHD patients had 
reduced neural activity in the ventral striatum upon receiving an 
award.68 This is in line with previous studies showing that ADHD 
patients are averse to delays and have reduced emotional reactions when 
receiving an award.  
Timing Network 
Studies looking at the timing network in ADHD patients during an 
assigned task found that the left inferior frontal gyrus, insula, 
cerebellum, and left parietal lobe were consistently under-activated.69  
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MICROSTRUCTURAL DIFFERENCES 
Dopamine Active Transporter Density 
PET and SPECT allow researchers to study the metabolic activity, 
cerebral perfusion, receptor binding potentials, and neurotransmitter 
turnovers within the brain.47 Traditionally, PET and SPECT were used to 
study changes in neurotransmitter binding and receptor density.70 
Recently, PET and SPECT techniques have been used to compare the 
availability of striatal dopamine transporters between ADHD patients and 
healthy controls.71 A meta-analysis found that ADHD patients had a 14% 
higher striatal dopamine active transporter (“DAT”) density than healthy 
controls did.72 Further analysis found that within ADHD patients, those 
who were medication naive had a lower density of dopamine transporters 
than those who had previously been medicated suggesting that a defect 
in DAT may contribute to ADHD.72  
Dopamine Receptor Density 
PET/SPECT was also used to compare the availability of dopamine D2 
and dopamine D3 receptors in the post-synaptic neurons of ADHD 
patients. Results showed that medication naïve ADHD patients had an 
overall decrease in dopamine receptor availability in the left caudate 
nucleus compared to their medicated peers.73 Most notably, the level of 
  36 
dopamine activity in these individuals did not change upon taking 
methylphenidate. 73 Previous SPECT studies showed that dopamine D2 
receptors were significantly decreased in ADHD patients throughout all 
levels of the striatum. As a result, methylphenidate had little to no effect 
on dopamine activity in these individuals.74 
VI. INFLUENCE OF SEX ON ADHD 
In the past, ADHD research was mainly centered around boys. In part, 
this was due to the belief that ADHD was a childhood disorder that 
remits upon adulthood. In addition, ADHD symptoms commonly present 
as hyperactivity-impulsivity in boys and inattentiveness in girls. Since 
hyperactivity-impulsivity symptoms are more noticeable than symptoms 
of inattentiveness, boys are reported to have ADHD at a higher rate than 
girls. As researchers began to learn more, they started to look what role 
sex plays in brain development and the effect it may have on ADHD.  
STUDY 1: DIFFERENCES IN REGIONAL CORTICAL ABNORMALITIES BY SEX  
In one study, researchers compared the neuroimages of children with 
ADHD to children without ADHD. A sex-matched peer analysis was then 
conducted to determine what role, if any, sex plays in the development of 
ADHD.75  
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The study focused on differences in cortical thickness and surface area 
in the prefrontal cortex and premotor cortex of children with ADHD. The 
results are shown in Figure 5 below. 
 
Figure 5. Comparison of Prefrontal Cortex Surface Areas in Girls with ADHD and 
Healthy Girls. (Left); Comparison of Premotor Cortex Surface Area in Boys with 
ADHD and Healthy Boys (Right).75 
PreFrontal Cortex 
Cortical Thickness 
When it came to cortical thickness, results showed that there were no 
significant differences found in the prefrontal cortex in children of either 
sex regardless of their ADHD status.75  
Surface Area 
Although both sexes with ADHD showed a reduced surface area in the 
prefrontal cortex as compared to neurotypical children, a sex-matched 
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analysis showed that the reduction was only significant in girls with 
ADHD. 75 Girls with ADHD exhibited reduced surface area throughout the 
prefrontal cortex while surface area reduction in ADHD boys was mainly 
limited to the left medial prefrontal cortex, right orbito-frontal cortex, and 
right anterior cingulate cortex.  
Premotor Cortex 
Cortical Thickness 
No significant differences in cortical thickness was found within the 
premotor cortex of either sex regardless of ADHD status. 75 
Surface Area 
Surface area reduction in the premotor cortex was found in the lateral 
premotor cortex and supplementary premotor cortex regions of children 
with ADHD. A comparison with sex-matched peers showed that ADHD 
boys had significant surface area reductions in the lateral premotor 
cortex as compared to neurotypical boys. While a sex-matched peer 
analysis of ADHD girls did not reveal any significant reductions, of the 
reductions that were found, most were in the supplementary premotor 
cortex.  
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Analysis of Results 
Analysis of the results showed that an increase in surface area of the 
prefrontal and premotor cortex was significantly associated with a 
decrease in ADHD symptom severity. 75 Surface area deficits in the 
prefrontal cortex predominantly impacted girls whereas surface area 
deficits in the premotor cortex predominantly impacted boys. 75 The 
results are summarized in Figure 6 below. 
 
 
Figure 6. Inverse Relationship Between Prefrontal Cortex Surface Areas and 
Symptom Severity in Children with ADHD (Left); Inverse Relationship Between 
Premotor Cortex Surface Areas and Symptom Severity in Children with ADHD 
(Right) 75 
Premotor Cortex Abnormalities in ADHD Boys 
ADHD boys with impairments in motor functions76 and motor inhibitory 
responses77 have decreased surface area in their premotor cortex. 75 
Previous studies have also pointed to premotor cortex abnormalities as a 
  40 
contributor to ADHD. In one study, researchers found that the mirror 
overflow movements commonly seen in boys with ADHD were 
attributable to a delay in cortical development. This delay resulted in a 
decreased ability to inhibit intracortical activities in ADHD boys.78 Other 
studies showed that ineffective neuronal pruning, resulting in a slower 
rate of cortical thinning, is positively correlated with ADHD symptoms of 
hyperactivity-impulsivity.79  
Prefrontal Cortex Abnormalities in ADHD Girls 
Previous studies showed that ADHD impairments in girls are often 
related to planning and task switching, both of which are controlled by 
the medial prefrontal cortex and dorsal lateral prefrontal cortex.77 This is 
supported by results from the current study, which showed an overall 
decrease in prefrontal cortex surface area, including the medial 
prefrontal cortex and the dorsal lateral prefrontal cortex.75  
Conclusion of Study 1 
Cortical surface area reduction in the brain are influenced by sex. In 
part, this can be attributed to the fact that brain development occurs 
earlier in neurotypical children of both sexes than in their ADHD 
counterparts.78 In addition, neurodevelopment occurs earlier in girls with 
ADHD than boys with ADHD.80 Since higher order association areas of 
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the brain, such as the anterior frontal lobe, is the last to develop, this 
may explain why ADHD children of the same age exhibit predominantly 
different symptoms when segregated by sex.75 Previous studies have also 
shown that the severity of ADHD symptoms can be correlated to the rate 
of cortical thinning.81 Together, these findings suggest that differences in 
ADHD presentations between boys and girls can be attributed to the 
influence sex has on brain development.  
STUDY 2: DIFFERENCES IN REGIONAL VOLUMETRIC ABNORMALITIES BY SEX 
Using VBM, researchers compared the gray matter volumes between 
treatment naïve ADHD children and their neurotypical peers.82 A sex-
matched analysis showed that in the anterior cingulate cortex, ADHD 
girls had increased gray matter volume compared to neurotypical girls 
while ADHD boys had decreased gray matter volume compared to 
neurotypical boys. 82 Results of the study showing sex-based gray matter 
volume differences within the anterior cingulate cortex are shown in 
Figure 7 below. 
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Figure 7. Gray Matter Volume Differences in Children with ADHD and Healthy 
Children as Segregated by Sex.13 
 
The anterior cingulate cortex is central to emotional regulation and can 
produce positive emotions as well as inhibit conditioned fear.83 Therefore, 
differences in gray matter volume within the anterior cingulate cortex 
may contribute to the emotional dysregulation often found in ADHD 
patients. 82  
Anterior Cingulate Cortex Abnormalities in ADHD Boys 
 A decrease in gray matter volume in the right anterior cingulate cortex 
has been associated with increased aggression in neurotypical boys.84 
This region is also decreased in boys with ADHD and may explain in 
part, the impulsive behaviors commonly seen.82 
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Anterior Cingulate Cortex Abnormalities in ADHD Girls 
On the other hand, increased gray matter volume in the right anterior 
cingulate cortex has been linked to excessive worrying and pessimism in 
both sexes.85 Past studies have shown that females with internalizing 
disorders tend to have an increase in gray matter volume within this 
region.86 Therefore, an increase in gray matter volume in the anterior 
cingulate cortex may explain the internalizing symptoms commonly 
found in ADHD girls.87  
VII. BRAIN DEVELOPMENT  
GRAY MATTER DEVELOPMENT 
There has been debate about whether the effect sex has on brain 
development and ADHD symptoms extends past childhood. Previous 
studies consistently found that children with ADHD have a lower total 
brain volume, specifically in the caudate nucleus, compared to healthy 
peers.88 Some studies suggest that this difference persists until 
adulthood while others maintain that the opposite is true.89  
Volumetric Differences in the Caudate Nucleus by Sex 
In one study, researchers conducted a volumetric analysis of the total 
gray and white matters in adults with ADHD with a particular focus on 
the accumbens, caudate, globus pallidus, putamen, thalamus, amygdala, 
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and hippocampus.48 Results showed no significant differences in brain 
matter volume existed between adults with ADHD and healthy adults. 
This suggests that differences in total brain volume is likely attributed to 
a delay in brain maturation and that brain volume will normalize by 
adulthood.36  
 
Although no significant differences in total brain volume were found 
based on ADHD status, this was not the case when results were 
segregated by sex. 36 Results showed that adult males with ADHD had a 
reduced volume in the right caudate nucleus when compared to adult 
male controls.36 This volume difference was not present in adult females 
regardless of ADHD status. 36 This finding suggests that the neurological 
basis of ADHD in adults is influenced by sex and may have a partially 
distinct underpinning from that in children. 36 
Caudate Nucleus Volume and Symptoms of Hyperactivity-
Impulsivity  
A linear regression analysis of the results showed that a reduction in the 
right caudate nucleus volume was associated with an increase in ADHD 
symptoms, primarily hyperactivity-impulsivity.36 The caudate nucleus, 
part of the extrapyramidal motor system, is key to motor control90 and 
inhibitory control.91 Previous longitudinal studies have shown that 
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caudate volume in ADHD children typically normalizes by adulthood.92 
This is consistent with clinical studies showing a decrease in 
hyperactivity-impulsivity symptoms with increasing age.93 The result 
suggests that persistent volume reduction in the caudate nucleus may be 
responsible for adults with ADHD who are still experiencing symptoms of 
hyperactivity-impulsivity.36 
 
The correlation between right caudate nucleus volume and symptoms of 
ADHD in ADHD adult males is shown in Figure 8 below.  
 
 
Figure 8. Correlation Between Right Caudate Nucleus Volume and ADHD 
Symptoms in Adult Males with ADHD36 
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Aside from brain volume differences in the right caudate nucleus of adult 
ADHD male patients, no significant differences of interest were found. 36 
This finding is in line with previous studies, which found that the 
structural brain abnormalities typically found in ADHD patients largely 
normalizes by adulthood.36 
WHITE MATTER DEVELOPMENT 
Unlike studies in gray matter, studies on the differences in white matter 
development in ADHD patients are sparse. Previous DTI studies revealed 
that white matter development continues into adulthood,94 with the most 
prominent development occurring in the anterior thalamic radiations and 
corpus colosseums.95 
 
Children with ADHD have been shown to have an overall reduction in 
white matter volume as compared to their healthy peers.92 By the time 
they reach adulthood, however, these children will typically have an 
increased amount of white matter as compared to their non-ADHD 
peers.96 This difference is thought to be due to disturbances in white 
matter maturation, with the most prominent effects seen in the 
frontostriatal tract and the superior longitudinal fascicules.97  
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A Study: The Role of White Matter Development in ADHD 
Regions of Interest  
One research studied the effects of white matter development in 
treatment naïve ADHD children and adults.98 Using DTI, researchers 
analyzed four regions of interest using fractional anisotropy: whole brain, 
anterior thalamic radiations, corpus collosum, and superior longitudinal 
fasciculus. 98 The results, shown below in Figure 9, were then age-
matched and compared. 
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Figure 9. Comparison of Mean White Matter Fractional Anisotropy of Children and 
Adults with and without ADHD 99  
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White Matter Differences: Healthy Children and Healthy Adults 
The results showed that fractional anisotropy radiations in healthy 
children were lower than those in healthy adults. 98 Since white matter 
crossings are inversely related to fractional anisotropy,99 this suggests 
that normal brain development is accompanied by white matter pruning. 
The MRI results comparing the fractional anisotropy in the corpus 
collosum and anterior thalamic radiation between neurotypical children 
and neurotypical adults are shown below in Figure 10. 
 
 
Figure 10. Comparison of White Matter Fractional Anisotropy Between Healthy 
Children and Healthy Adults99 
 
White Matter Differences: ADHD Adults and Healthy Adults 
Between ADHD adults and their healthy peers, white matter differences 
were most prominently seen in the anterior thalamic radiations and 
corpus collosum.98 In both regions, the fractional anisotropy in the 
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control group was higher than those in the ADHD group. 98 An increase 
in fractional anisotropy is correlated to a decrease in white matter fiber 
tracts. The results, therefore, show that the number of white matter 
crossings in healthy adults are less than those in adults with ADHD. 
This suggests that the neuronal pruning typically associated with normal 
brain development did not occur in adults with ADHD.100 
 
Anatomically, the anterior thalamic radiations are responsible for 
connecting the thalamus with the prefrontal and orbital frontal cortex.101 
These regions play a key role in executive function, decision making, 
reward response, sensory-motor function, and oculomotor function.98 
The superior longitudinal fasciculus, on the other hand, is responsible 
for mediating attention and executive function performance.102 Abnormal 
white matter connections within these regions contribute to the 
difficulties typically seen in ADHD patients.98 MRI results comparing the 
fractional anisotropy in the corpus collosum, anterior thalamic 
radiations, and superior longitudinal fasciculus between adults with 
ADHD and their age-matched peers are shown below in Figure 11. 
 
Figure 11. Comparison of White Matter Fractional Anisotropy Between Adult with 
ADHD and Healthy Adults98 
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White Matter Differences: ADHD Children and Healthy Children 
Unlike adults, DTI analysis revealed no differences in fractional 
anisotropy between ADHD children and their age-matched peers.98 This 
suggests that ADHD may be a developmental disorder103 attributable to a 
delay in white matter maturation. This would explain why differences in 
fractional anisotropy and white matter crossings in ADHD patients are 
typically not seen until late adolescence.98 MRI results showing age-
dependent changes in the anterior thalamic radiation of ADHD patients 
are shown below in Figure 12. 
 
Figure 12. Age-Dependent Changes in White Matter Fractional Anisotropy Patients 
with ADHD (Top); Age-Dependent Changes in White Matter Fractional Anisotropy 
of Healthy Controls (Bottom).98  
 
VIII. GENETICS BASED STUDIES 
Extending the scope of ADHD beyond the individual, researchers began 
looking at the first-degree relatives of ADHD patients to see whether a 
genetic basis for the disorder exists.  
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HEREDITABILITY STUDIES 
Family 
Researchers noticed that a high correlation rate existed between 
individuals exhibiting ADHD symptoms and their nuclear family. To 
further understand this correlation, additional clinical research involving 
identical twins as well as first-degree relatives were conducted. 
Identical Twins 
Noticing that symptoms of ADHD tend to run in families, researchers 
decided to look at identical twins to see whether ADHD can be inherited. 
One study found that twins have up to an 80% chance of inheriting the 
disorder while first-degree relatives have up to a 10-fold risk of being 
ADHD positive themselves.104 Although researchers were able to 
establish these correlations, a definitive gene contributing to ADHD has 
yet to be found. Researchers speculate that this is because ADHD is a 
complex polygenic disorder.47 
Unaffected First-Degree Relatives 
Despite the 10-fold increased risk of being ADHD positive, not all first-
degree relatives of ADHD individuals go on to develop the disorder. For 
those first-degree relatives that remain ADHD free, one researcher, 
Valentino Antonio Pironti, decided to conduct a neuroimaging study to 
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see whether these first-degree relatives shared similar brain 
abnormalities with their ADHD relatives. A non-ADHD group was also 
included in the study as a control. The brain area of interest in this 
study was the cingulo-fronto-parietal region, which controls cognition 
and attention.105 
Gray Matter 
VBM showed that ADHD patients had a significantly decreased amount 
of gray matter volume in the right inferior frontal gyrus as compared to 
healthy controls. Interestingly, the gray matter volume in the unaffected 
first-degree relatives was markedly similar to those with ADHD.100 The 
gray matter volume of each group is shown below in Figure 13. 
 
Figure 13. Comparison of Gray Matter Difference in the Right Inferior Frontal 
Gyrus Between ADHD Patients, Unaffected First-Degree Relatives, and Healthy 
Controls100 
 
  54 
Imaging showed that, when compared to the control group, ADHD 
probands had increase gray matter in the left middle occipital gyrus, 
superior occipital gyrus, and the left dorsal mid-cingulate cortex. 
Interestingly, imaging results from the unaffected first-degree relatives 
overlapped with both groups.100 The gray matter volumes of each group 
are shown below in Figure 14. 
 
Figure 14. Comparison of Gray Matter Differences in Several Regions of the Brain 
Between ADHD Patients, Unaffected First-Degree Relatives, and Healthy 
Controls100  
 
White Matter 
Pironti further analyzed the white matter volume in all three groups and 
found that ADHD patients and their unaffected first-degree relatives have 
a significantly higher white matter volume than the control group.100 The 
volume increase was mainly located in the posterior portion of the right 
inferior fronto-occipital fasciculus and can be seen in Figure 15. 
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Figure 15. Comparison of White Matter Differences in the Right Inferior Fronto-
Occipital Fasciculus Between ADHD Patients, Unaffected First-Degree Relatives, 
and Healthy Controls100 
 
Cognitive Measure Tests 
Comparing the neuroimages of the three groups elucidated the type and 
degree of brain abnormalities present in ADHD patients and their 
unaffected first-degree relatives. However, without additional cognitive 
based testing, it is hard to know whether these abnormalities correlated 
with a decrease in performance score across all three groups equally.  
 
The first test was the Rapid Visual Information Processing Test of 
Sustained Attention, which measured attentiveness. The second test was 
the Stop Signal Reaction Time Test, which measured inhibition. 
 
As expected, the ADHD group scored the lowest while the non-ADHD 
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control group scored the highest on both tests. The unaffected first-
degree relatives on the other hand, scored similarly to those with ADHD 
on the Rapid Visual Information Processing Test of Sustained Attention 
Test. On the Stop Signal Reaction Time Test, the unaffected first-degree 
relatives group scored slightly higher than ADHD group but lower than 
the control group.100 The results of both tests are shown below in Table 3 
and Figure 16. 
 
Table 3. Results of Cognitive Measure Tests in ADHD Patients, Unaffected-First 
Degree Relatives, and Healthy Controls100 
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Figure 16. Comparison of Measuring Sustained Attention Between ADHD Patients, 
Unaffected First-Degree Relatives, and Healthy Controls100 
 
Correlation Between Neuroimages and Cognitive Measure Tests 
Neuroimaging results showed that the right inferior frontal gyrus and the 
inferior occipital fasciculus in ADHD patients were different from those in 
healthy controls. By correlating the neuroimages with results from the 
cognitive measure test, researchers hoped to gain additional insight into 
the role gray and white matter play in ADHD. The results of this 
correlation study are shown below in Figure 17. 
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Figure 17. Positive Correlation Between Gray Matter in the Right Inferior Frontal 
Gyrus and Sustained Attention (Left); Negative Correlation Between White Matter 
in the Right Inferior Fronto-Occipital Fasciculus and Inhibitory Control (Right)100 
Gray Matter and Cognitive Measure Tests 
The right inferior frontal gyrus is responsible for attention allocation 
upon noticing a stimulus,106 regardless of whether the stimulus response 
is an inhibitory one or not. 106 Results from this study showed that an 
increased volume in this region is associated with an increased ability to 
sustain attention as measured by the Rapid Visual Information 
Processing Test of Sustained Attention.  
 
Similar results between ADHD patients and their unaffected-first-degree 
relatives show that the ability to sustain attention is determined by 
genetics and has a heritability rate of 60%.107 Continued studies into this 
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region of the brain may help identify additional factors that contribute to 
ADHD. 
White Matter and Cognitive Measure Tests 
The right fronto-occipital fasciculus is associated with executive 
performance. 
Results from this study showed that an increased volume in this region 
is associated with decreased inhibitory control as measured by the Stop 
Signal Reaction Time Test.100 The fronto-occipital fasciculus is therefore 
associated with both executory and inhibitory control. This suggests that 
a decrease in inhibitory control may be partially responsible for the 
executive function deficits seen in ADHD patients.108 Approximately one-
third of the variance found in the inferior fronto-occipital fasciculus is 
genetically driven.109 This finding is consistent with and would explain 
the similar scores on the Stop Signal Reaction Time Test between ADHD 
patients and their unaffected first-degree relatives.  
 
The number of white matter tracts in the right fronto-occipital fasciculus 
is negatively correlated with inhibitory control. Neurotrophic factors such 
as brain-derived neurotrophic factor (“BDNF”) are responsible for axon 
myelination and neuronal growth.100 Given the neuronal overgrowth and 
myelination often seen in ADHD patients, inefficient neuronal pruning 
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resulting in an increase in white matter may be a key contributor to 
ADHD.110 
Shared Abnormalities with ADHD Patients 
Overall, Pironti’s study shows that while unaffected first-degree relatives 
of ADHD patients may not express symptoms of ADHD, nevertheless they 
still share similar brain abnormalities and cognitive measurement 
deficiencies as their ADHD relatives.100 Since brain structure and neural 
circuitry are highly hereditable, studies linking brain abnormalities with 
a decrease in cognitive performance suggest that variance in gene 
expression may be partially responsible for an individual developing 
ADHD. Past studies showing the heritability estimates of certain regions 
of the brain are shown below. Heritability estimates are defined as the 
percentage of phenotypic variance that can be attributed to genetic 
variance at the population level. Not all regions of the brain are equally 
heritable. In addition, cortical surface area has a higher rate of 
heritability than cortical thickness.111  
Regions of Interest with High Heritability Estimates  
• Frontal Lobe Volume: 0.90 – 0.95112  
• Region-Based Cortical Surface Areas: 0.48-0.77112  
• White Matter  
o Global Fractional Anisotropy: 0.55113 
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o Radial Diffusivity: 0.72113  
o Functional Connectivity in the Default Mode Network: 
0.42113 
Regions of Interest with Moderate Heritability Estimates 
• Hippocampus Volume: 0.40 – 0.69112  
• Cerebellum and Cerebral Cortex Volume: 0.50 – 0.65114 
Together with Pironti’s study, these heritability estimates further 
supports the theory that ADHD is a highly heritable disease. 
GENOME-WIDE ASSOCIATION STUDIES 
Genetic linkage studies first began in the early 2000s,47 Since then 
several meta-analyses have been conducted in this area. One meta-
analysis found that a locus on the short arm of chromosome 16, 
potentially the CDH13 Cadherin-13 gene,115 may be associated with 
ADHD.116 Another gene of interest is LPHN3, Latrophilin 3, found on 
chromosome 4. Since then, additional testing has confirmed that LPHN3 
plays a role in ADHD.116 
Copy Number Variations and Single Nucleotide Variations 
Genetic linkage studies paved the way for genome-wide association 
studies. Researchers hoped to identify a single locus of genomic-wide 
level of significance.117 Although such locus was never found, a genome-
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wide analysis showed that rare copy number variants and rare single 
nucleotide variants contribute to ADHD.  
Neuroimages as Endophenotypes 
Several genes appear to have a higher rate of association with ADHD 
than others. These genes are: SLC6A3 /DAT1, which encodes for 
dopamine transporters; DRD4, which encodes for dopamine D4 
receptors; SLC6A4/5HTT, which encodes for serotonin transporters; and 
HTR1B Gene, which encodes for serotonin receptors. These genes of 
interest will be discussed further in this section below. 
 
Building on genome-wide association studies, researchers decided to look 
at both copy number variants and single nucleotide variants of these 
genes to see whether their biological underpinnings can shed additional 
light on ADHD.47 This was done using brain images as endophenotypes 
in hopes that the structural abnormalities detected in the brain can be 
correlated to genetic abnormalities in the individual. 
 
Endophenotypes, also known as intermediate phenotypes, allow 
researchers to detect the pathological basis of a disorder that contributes 
to the final clinical outcome.118 Endophenotypes can best be described as 
“those characteristics of a disorder that are linked more closely to its 
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neurobiological substrates than its clinical symptoms”119 and “[those 
that] share genetic susceptibility factors with the disorder itself.”120  
IMPORTANT GENES OF INTEREST 
SLC6A3 /DAT1 Gene: Dopamine Transporter 
SLC6A3 /DAT1 is responsible for encoding dopamine transporters. This 
transporter is responsible for reuptake of the dopamine from the synaptic 
cleft into the presynaptic neuron,47 and is one way in which dopamine is 
regulated in the striatum.121 Given the important role dopamine plays in 
attention, variations in this gene could result in symptoms of ADHD.  
SLC6A3 /DAT1: Copy Number Variations  
Research showed that a 40 base pair long region located in the 3’ 
untranslated region (“UTR”) of the SLC6A3/DAT1 gene was responsible 
for regulating dopamine activity in the striatum.47 This region is heavily 
subject to copy number variations in patients with ADHD. These 
variations typically consist of tandem repeats, with the most common 
repeats in ADHD patients associated with the 9 Repeat (“9R”) Allele and 
the 10 Repeat (“10R”) Allele.47 Within intron-8 of the same gene, a 30-
basepair long region is also highly susceptible to copy number variations. 
47 The most common alleles responsible for this genetic variation in 
ADHD individuals typically encodes for 5 Repeats (“5R”) or 10R. 47 
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Association with Increased Risk of ADHD 
Further clinical testing revealed that children at risk of developing ADHD 
typically expresses a 10R/10R genotype in the 3’ UTR region of 
SLC6A3/DAT1. The presence of a 10R haplotype in the 3’ UTR region and 
6 Repeat (“6R”) copy number variation in intron-8 also increases the risk 
of ADHD in children.122 Interestingly, copy number variations in intron-8 
alone were shown to have no effect in DAT binding and therefore, is 
thought to not cause ADHD on its own.47  
Association with Persistent ADHD 
Meanwhile, 9R/9R genotype found in the 3’ UTR region of the 
SLC6A3/DAT1 is associated with persistent ADHD. A haplotype 
consisting of 9R in the 3’ UTR region and 6R in intron-8 also leads to the 
same result.123 Through PET, scientists have identified the 9R/9R 
genotype in the 3’ UTR of the SLC6A3/DAT1 gene which results in 
increased dopamine binding in the caudate nucleus independent of 
ADHD status. 47 It is still unclear why some 9R/9R individuals go on to 
develop persistent ADHD while others do not. The fact that different copy 
number variances in the SLC6A3/DAT1 gene lead to different outcomes 
suggest that the gene modulates the effect of ADHD.  
 
Further SPECT studies showed that when methylphenidate was 
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administered to ADHD children carrying the 10R/10R genotype during a 
continuous performance task-test, there was an increase in DAT density 
and cerebral blood flow to the basal ganglia. 124 The response in ADHD 
children carrying the 9R allele did not yield the same results.124  
 
Notably, the same study when done on adults showed no difference in 
DAT availability between the 10R/10R group and the 9R carrier group.125 
Together these studies showed that the 9R allele is associated with an 
increase in DAT independent of ADHD status.47  
Dopamine Transporter Gene: Single Nucleotide Polymorphism 
Single nucleotide polymorphism (“SNP”) also plays an important role in 
ADHD. One study studied looked at two SNP haplotypes, rs2652511 and 
rs2937639, in the 5’ regulatory region of SLC6A3/DAT1. Researchers 
discovered that a CG-allele in this region was associated with DAT 
availability in the ventral striatum independent of ADHD status. 47  
DRD 4 Gene: Dopamine D4 Receptor 
Another gene of interest is the Dopamine Receptor D4 (“DRD4”) gene, 
which encodes for G-coupled dopamine D4 receptors. 47 In ADHD 
individuals, DRD4 gene is most commonly expressed in the orbitofrontal 
cortex and the anterior cingulate cortex.126 Polymorphisms in this region 
  66 
are shown to affect dopamine D4 receptor binding, resulting in a 
decreased dopamine response. 47 
The most common polymorphism of the DRD4 gene is a copy number 
variation of the 48 base pairs located in exon-3. The copy number 
variations are expressed by three alleles, resulting in 2 Repeats (“2R”), 4 
Repeats (“4R”) and 7 Repeats (“7R”). 47 The frequency of these alleles 
varies across ethnic groups127 with the 7R allele being the most common 
in the Caucasian population.128 Each of these alleles affects the neuro-
structure and neuro-circuitry of the brain differently.  
DRD4: 4R Allele 
Children homozygous for the 4R allele were found to have a smaller 
prefrontal grey matter volume.129 This effect was particularly pronounced 
in their unaffected first-degree relatives.129 
DRD 4: 7R Allele  
Adult ADHD patients carrying the 7R allele was shown to have a smaller 
superior frontal and cerebellar cortex.47 In addition, 7R carriers were 
found to have a thinner prefrontal cortex and parietal cortex. A delay in 
cortical maturation is also observed although normalization of the cortex 
is often achieved in the end.130  
  
  67 
Results showed that 7R allele carriers had reduced cortical activation131 
and scored lower on the inhibitory control and sustained attention task-
tests132 than the non-7R allele carriers, independent of ADHD status.131  
 
Since individuals with longer copy number variants in their DRD4 genes 
experienced a decrease in executive function abilities, this illustrates the 
effect the DRD4 gene has on ADHD.133 
HTR1B Gene: Serotonin Receptor 
One of the most commonly studied serotonin receptors in ADHD 
research is the G-protein coupled receptor, 5-Hydroxytryptamine 
Receptor 1B, (“HTR1B”) encoded by the HTR1B gene.134 The HTR1B gene 
is expressed abundantly in the dorsal raphe nucleus, which regulates the 
sleep-wake cycle135. Studies show that within nuclear families affected by 
ADHD, the G-allele of rs6296 was preferentially transmitted to their off-
springs.136 This suggests that ADHD may be a hereditary disorder. 
SLC6A4/5HTT Gene: Serotonin Transporter 
Another gene of interest is SLC6A4/5HTT which encodes for serotonin 
transporters that are responsible for reuptake of serotonin from the 
synaptic cleft.137 A 44-basepair long functional polymorphism exists in 
the functional promotor region of SLC6A4/5HTT.137 This polymorphism 
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is responsible for insertions and deletions resulting in a short allele and 
a long allele. Carriers of the long allele have increased serotonin reuptake 
resulting in lower serotonin levels in the brain.137 Since serotonin 
transporters are typically expressed in regions associated with attention 
and memory,138 it is unsurprising that the presence of rs25531 within 
the long allele affects these functions.139 The short allele is more 
commonly associated with depression and anxiety than ADHD.140 
However, several studies have found that upon exposure to 
environmental stress, those carrying the short allele may have an 
increase in ADHD severity.141 This suggests that in addition to genetics, 
the environment may also play a role in ADHD.  
OTHER GENES OF INTEREST 
In addition to the genes discussed above, there are three less commonly 
studied genes, ADRA2A, COMT gene, and SNAP25 gene, that are also 
important contributors to ADHD. These genes are discussed below.  
ADRA2A Gene: Alpha-2a-Adrenergic Receptor 
Another gene of interest is the alpha-2A-adrenergic receptor (“ADRA2A”) 
gene which encodes for ADRA2A. This is the most commonly found 
noradrenergic receptor in the prefrontal cortex142 Adrenergic 
neurotransmitters play a key role in attention and executive control.142 
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There are two SNPs located in the promotor region of the ADRA2A gene 
that are highly associated with ADHD. The first SNP is rs1800544. G-
allele carriers of this SNP are thought to be at an increased risk of 
ADHD. The second SNP is rs553668. T-allele carriers of this SNP are 
thought to be at an increased risk of ADHD.143 SPECT studies showed 
that normal allele carriers of rs1800544 have decreased blood flow to 
both orbitofrontal regions of the brain.144 In addition, normal allele 
carriers of rs553668 show reduced fractional anisotropy in the right 
postcentral gyrus of the brain. This is in comparison to T-allele carriers 
of rs553668 who have reduced fractional anisotropy in the right middle 
frontal cortex of the brain.145 Given the importance of adrenergic 
neurotransmitters in sustaining attention, these differences in SNPs may 
contribute to the inattentive symptoms seen in ADHD. 
COMT Gene: Catechol-0-Methyl-Transferase 
The catechol-o-methyl-transferase (“COMT”) gene, located at 22q11.21, is 
responsible for encoding COMT. COMT is responsible for degrading 
catecholamines such as dopamine and norepinephrine in the frontal 
lobe.47 Within exon 4 of the COMT gene, the presence of SNP rs4860 
results in valine being substituted for methionine.47 This substitution 
significantly affects COMT activity. Studies show that 
methionine/methionine carriers have up to four times lower COMT 
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activity than their valine/valine counterparts. 47 This results in 
homozygous methionine carriers having substantially lower amounts of 
catecholamines.146 Further analysis revealed an association between the 
rs4860 allele and the reward neurocircuitry in the brain.147 
 
Studies also showed that children carrying at least one methionine allele 
had reduced grey matter volume in the insula and inferior frontal gyrus 
compared to children without the allele.148 These children were also 
found to have decreased gray matter volume in the caudate nucleus148 
and left when compared to children who were homozygous for the valine 
allele.  
 
A DTI study showed that the white matter connections in methionine-
allele carriers were weaker than those in valine-allele carriers.150 This 
suggests that the methionine-allele of rs4860 is involved in white matter 
maturation and connectivity151 and may contribute to symptoms of 
ADHD. 
SNAP Gene: Synaptosomal-Associated Protein 25 
Synaptosomal-Associated Protein 25 (“SNAP25”) is encoded by the 
SNAP25 gene. SNAP25 is important in maintaining synaptic plasticity 
and axonal growth. Snap25 is also responsible for docking and fusion of 
  71 
vesicles in the pre-synaptic neuron and therefore plays an important role 
in regulating neurotransmitter release.152 
 
Studies show that in children who are T-allele carriers of SNP rs3746544 
have a higher risk of ADHD.153 In one study, researchers used fNIRS to 
compare the hemodynamic changes in the prefrontal cortex of ADHD 
patients taking methylphenidate. 47 fNIRS were then segregated by T-
allele carrier status and compared.154 In homogenous T-allele carriers, 
changes in hemoglobin level in the prefrontal cortices were observed. 
Given that T-allele carriers of rs3746544 have a higher risk of developing 
childhood ADHD, researchers hoped that the hemodynamic changes 
observed in this study will shed additional light on the role T-allele has in 
ADHD.154 
IX. TREATMENT 
Psychosocial and medication-based treatments are available for patients 
with ADHD. While medication is the core treatment of ADHD, 
psychosocial treatment also has a role in supporting patients who are 
not responsive to medications. By studying the mechanism of actions 
behind treatments that have a high rate of success, researchers hope to 
discover additional clues behind the etiology of ADHD.  
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PSYCHOSOCIAL TREATMENT 
 Psychosocial treatments, the most common one being cognitive 
behavioral therapy, play an important role in helping ADHD patients 
manage their symptoms.23 Psychosocial treatments are more commonly 
used as an adjunct to medications rather than as a mainstay.23 Despite 
their adjunctive role, psychosocial treatments serve an important 
purpose for patients who do not respond well to medication or patients 
that suffer from ADHD related inter and intra-personal difficulties that 
cannot be treated by medication alone.  
Antecedent/Consequence Model 
The Antecedent/Consequence Method is a tool commonly used by 
parents and teachers to manage ADHD in children.23 Antecedent 
intervention commonly focuses on signs that precede behavioral 
problems so that the parent or teacher can redirect the child’s attention 
towards something more appropriate with the goal of reinforcing this 
behavior through reward. Consequence intervention, on the other hand, 
is used when the undesired behavior has already occurred and focuses 
on using appropriate punishment to deter such behaviors in the future. 
23 Psychotherapy often plays an important role in treating certain areas 
of a patient’s life, such as performance, social-interpersonal 
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relationships, and adaptive behavior problems, that have been impaired 
by ADHD.33  
PSYCHOSOCIAL TREATMENT VS. MEDICATION 
Despite the role psychotherapy has in ADHD management, it cannot 
replace the need for medication. 6 An NIH study showed that medication 
alone is more effective in treating ADHD symptoms than non-medication-
based treatments.156 Psychotherapy in conjunction with medication-
based treatment was shown to be more effective at treating ADHD than 
medication alone, especially in individuals with inattentive symptoms.157  
In a landmark study, 579 ADHD children were given one of the following 
treatments for fourteen-months: medication, psychosocial, medication 
with psychosocial, and community control.158 At the end of the trial, 
results showed that those who received medication and medication with 
psychosocial treatment experienced the greatest amount of improvement 
in ADHD symptoms.2 Children in the psychosocial and community 
control groups experienced similar rates of improvements when 
compared to each other but lagged behind groups that received 
medication.2 A 24-month follow-up with patients that received 
medication and medication with psychosocial treatment showed that 
while symptoms of their ADHD continued to improve, the effects of their 
improvement were significantly diminished.2 
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In another study, researchers compared the outcomes of patients using 
medication with psychotherapy and patients using medication with 
standard clinical management.33 Surprisingly, even though variability 
was initially present in the trial, both groups had the same outcome, 
indicating that psychotherapy is no more effective than standard clinical 
management is in treating ADHD patients. 6 Despite similar outcomes, 
using psychotherapy in conjunction with medication as part of a 
treatment regimen may prove beneficial to ADHD patients who are less 
responsive to medication. 6  
MEDICATIONS 
Medications used in treating ADHD can be divided into stimulants and 
non-stimulants. Stimulants are first-line agents used in treating patients 
with ADHD due to their efficacy and safety.159 Stimulants reduce 
symptoms of ADHD in approximately 70% of ADHD patients.160 
Commonly used non-stimulants are alpha-adrenergic agonists.6 Studies 
have shown that stimulants are more effective than alpha-adrenergic 
agonists in treating ADHD. However, a combined treatment of both types 
of medication is more effective than using either type alone.161 
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STIMULANTS 
Stimulants are sympathomimetic drugs that increase the amount of 
catecholamines, typically dopamine and/or norepinephrine, found in 
synaptic clefts. 6 This category of medication can further be sub-divided 
into methylphenidate-based, amphetamine-based, and atomoxetine-
based stimulants.  
Methylphenidate-Based Stimulants 
Common methylphenidate-based stimulants include Ritalin, Concerta, 
Focalin, Metadate, and Daytrana among others. Methylphenidate-based 
stimulants work by blocking dopamine transporters in the striatum and 
noradrenergic transporters in the frontal lobe. 6 
Amphetamine-Based Stimulants 
Amphetamine-based stimulants work like methylphenidate-based 
stimulants, but in addition also cause the release of dopamine and 
noradrenergic into the synaptic cleft.162 
 
Both types of methylphenidate-based and amphetamine-based 
stimulants come with risks of adverse effects such as upset stomach, 
insomnia, and reduced appetite which may lead to weight loss or 
anorexia.163 In addition, there is a risk of adverse cardiovascular events, 
  76 
though studies show that this risk is no higher in the ADHD population 
than in the general public.164 Patients with a history of heart disease 
should have their blood pressure monitored periodically for the duration 
of treatment. 6 
Atomoxetine-Based Stimulants 
Atomoxetine-based stimulants are potent inhibitors of norepinephrine 
reuptake transporters.165 Unlike methylphenidate and amphetamine-
based stimulants, the effects of atomoxetine are not seen until several 
weeks into treatment. As a result, this class of medication has a lower 
potential risk of abuse. Trials have shown that atomoxetine-based 
stimulants are effective in treating ADHD patients with comorbidities 
such as substance abuse disorder.166 
 
Common adverse effects of atomoxetine-based stimulants include 
gastrointestinal upset, nausea, and sedation. 6 On rare occasions 
atomoxetine may cause hepatitis. 6 As a result, this medication carries a 
black box warning and those with a history of liver disease should speak 
to their clinicians prior to starting treatment. 6  
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NON-STIMULANTS 
Alpha-Adrenergic Agonists 
The second category of ADHD medication is alpha-adrenergic agonists, 
which are non-stimulant based medications. Common alpha-adrenergic 
agonists used in treating ADHD include guanfacine and clonidine. 
Clonidine is an alpha-adrenergic agonist that affects all alpha receptors 
equally while guanfacine is more selective for alpha-2a receptors. 6 In 
addition to treating ADHD, alpha-adrenergic agonist medications also 
treat oppositional defiant behavior and sleep disorders in children and 
are therefore used in ADHD patients with comorbidities.167  
 
Common adverse effects of alpha-adrenergic agonists include fatigue, 
changes in mood, and rebound of hypertension if medications are 
discontinued abruptly. 6 
EFFECTS OF MEDICATIONS ON THE BRAIN  
A Study Using Methylphenidate  
One study sought to examine the effects stimulants have on brain 
function in ADHD patients. Researchers compared the fMRIs of two 
groups of medication naive ADHD adolescents with one group receiving 
methylphenidate and the other group receiving a placebo.160 Both groups 
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performed tasks that tested their inhibition, working memory, and time 
discrimination abilities while fMRIs of their brain activities were 
recorded. The results of the trial are shown below in Table 4 and Figure 
18. 
 
Table 4. Comparison of Regional Brain Activation During Cognitive Measure Tests 
in Untreated ADHD Boys and Methylphenidate Treated ADHD Boys160 
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Figure 18. fMRI Results Comparing Regions of Brain Activation in Untreated 
Children with ADHD and Methylphenidate Treated Children with ADHD During a 
Time Discrimination Test160 
The results are consistent with previous studies, which showed that 
administration of methylphenidate in ADHD patients resulted in 
increased activation and normalization of the right inferior frontal cortex 
and insula.160 The results of this study are shown below in Table 5 and 
Figure 19. 
 
Table 5. Results of an fMRI Meta-Analysis Comparing Regional Brain Differences 
in Untreated ADHD Patients and Methylphenidate Treated ADHD Patients160 
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Figure 19. fMRI Results Comparing Regions of Brain Activation in Untreated 
Children with ADHD and Methylphenidate Treated Children with ADHD. (A) Three-
Dimensional View; (B) Two-Dimensional View with p<0.005; (C) Two-Dimensional 
View with p<0.05160 
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The inferior frontal cortex and insula play a key role in cognitive 
control,168 saliency detection, sustained attention,169 and time 
discrimination.168 This region of the brain is consistently under-activated 
in ADHD patients.169 It is also the most activated region in ADHD 
patients taking methylphenidate.160  
 
Methylphenidate increases activation of the basal ganglia in ADHD 
patients, bringing them closer to their neurotypical peers. The basal 
ganglia is important for inhibitory control.160 Methylphenidate also 
decreases brain activity in the anterior cingulate cortex and 
supplementary motor areas of the brain in ADHD patients, bring their 
activity closer to normalized controls.160  
 
Although methylphenidate normalizes brain activities in ADHD patients, 
this did not translate into an increase in performance in this particular 
study.170 
MAINTENANCE RESPONSE PERIOD AND RATE OF RELAPSE 
ADHD is a chronic disorder that necessitates long term treatment with 
medications. Since ADHD symptoms are heterogeneous and dimensional, 
the dose and type of medication prescribed should be carefully monitored 
and adjusted according to patient needs. Currently, there is no 
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consensus on the duration of treatment in patients that respond well to 
medication.160 Even more unknown is the effect discontinuation of 
medications has on these individuals. 160 Given the paucity of data, one 
study decided to look at the rate of relapse in ADHD patients upon 
discontinuation of medications.171  
 
In adults, it was shown that patients taking atomoxetine had the lowest 
rate of relapse upon discontinuation of treatment. 171 Despite 
discontinuation of atomoxetine, some patients still experienced relief 
from ADHD symptoms. 171 This may be due to neurobiological changes 
that occurred during treatment.172  
 
In one animal study, it was shown that long term exposure to 
atomoxetine resulted in changes in the transcription and translation of 
N-methyl—D-aspartate and norepinephrine transporters. In addition, 
atomoxetine was found to increase BDNF in the prefrontal cortex. 171 
 
Compared to other medications, atomoxetine has the highest period of 
maintenance response at 25 weeks and the lowest rate of relapse at 7.4% 
upon discontinuation of the medication. 171 Although methylphenidate 
has a similar period of maintenance response as atomoxetine, it had the 
second highest rate of relapse at 75% when the medication was 
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discontinued. 171 This may be due to the different mechanisms of action 
underlying atomoxetine and methylphenidate. fMRI shows that 
atomoxetine activates the anterior cingulate cortex in the brain while 
methylphenidate activates the striatum. 171  
 
The results of the study are shown below in Table 6, Table 7, and Figure 
20. 
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Table 6. Maintenance of Response Period and Rate of Relapse of Atomoxetine, Methylphenidate, 
and Lisdexamfetamine in Adults with ADHD171
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Table 7. Rate of Relapse of Atomoxetine, Methylphenidate, and Lisdexamfetamine 
Upon Discontinuation in Adults with ADHD171 
 
 
Figure 20. Comparison of Maintenance of Response Rate in Adults with ADHD 
Taking Atomoxetine and Adults with ADHD Taking Placebo171 
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Currently, it is recommended that ADHD patients with a short-term 
response to medication, should continue the medication as long as it 
remains clinically effective. 171 For patients where long-term response can 
be achieved, clinicians should review their treatment plans annually to 
see whether any adjustments need to be made. 171 Regardless of the 
duration of response, patients who did not suffer from severe ADHD 
symptoms at baseline should be periodically assessed to see whether 
medication is still necessary. 171  
CONCERNS OVER RISK OF ABUSE 
As with any medications prescribed, there is a risk that medication 
abuse will occur. Critics of stimulant based ADHD medications are 
concerned that prescribing such medications may encourage patients to 
abuse their stimulant medications. However, there is a lack of data to 
support this concern.173 Instead studies show that ADHD patients who 
were prescribed stimulants had a reduced risk of cigarette smoking, 
substance abuse, 173 and developing comorbidities such as depression 
and anxiety.37 Although ADHD patients typically do not abuse their 
stimulant medications, studies show that these patients are also more 
likely to disperse stimulant medications to their non-ADHD peers.174 
Compared to extended-release stimulants, studies have shown that 
immediate-release stimulants are more at risk of being abused.175  
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X. CONCLUSION 
IMPORTANT MILESTONES  
While the precise etiology of ADHD is still unknown, researchers now 
know that the pathology behind ADHD can be attributed to differences in 
brain development and connectivity. These, in turn, are influenced by 
factors such as sex, age, and genetics. Researchers found that girls with 
ADHD have decreased prefrontal cortex surface area while boys with 
ADHD have decreased premotor cortex surface area. The inattentive 
symptoms and hyperactivity-impulsivity symptoms seen in ADHD girls 
and boys, respectively, can be attributed to these differences in the brain. 
In addition, age also plays a role in ADHD. By adulthood, differences in 
gray matter brain volume largely normalize. This corresponds to studies 
which show that ADHD patients experience less hyperactivity-impulsivity 
as their brain develops.  
 
ADHD is also driven by genetics as the heritability estimates for certain 
regions of the brain reaches such as the frontal lobe reaches as high as 
0.95. Neuroimaging studies have also shown that ADHD patients and 
their unaffected first-degree relatives share similar brain abnormalities. 
Although ADHD patients and their unaffected-first degree relatives may 
express similar endotype and genotype, the phenotype displayed can be 
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drastically different. An explanation as to why ADHD manifests in one 
individual but not another despite both having an at-risk gene may be 
due to a myriad of factors including environmental interactions and 
other life stressors. 
 
Molecular research also yielded important clues as to the effect 
variations in alleles have on ADHD, especially for major contributing 
genes such as those encoding for dopamine transporter/receptor and 
serotonin transporter/receptor. Despite all the advancement made, 
researchers have yet to identify a single major contributing gene to 
ADHD. This is most likely because ADHD is a polygenic disorder. 
 
Being able to identify the first signs of ADHD allows parents, teachers, 
and providers to intervene as early as possible. This is especially 
important given the high rate of comorbidities such as depression, 
anxiety, and substance abuse, that often accompany these patients. 
Early intervention significantly decreases the negative long-term impact 
ADHD can have their quality of life, staving off unwanted effects such as 
lower education, lower income, and unfulfilling relationships. 
 
Despite not knowing its precise etiology, researchers have been able to 
discover enough about ADHD to formulate a treatment regime for the 
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disorder. While psychosocial therapy are important adjuncts, stimulant-
based medications remain the first-line of therapy in ADHD. Research 
showed that untreated ADHD patients are more likely to abuse drugs 
than treated ADHD patients. This may be due to untreated ADHD 
patients unconsciously attempting to self-medicate their symptoms. 
 
Stimulant-based medications have garnered many oppositions as 
stimulant abuse is on the rise. Some of these oppositions have reached 
as far as claiming that ADHD is not a true disorder, but rather a 
reflection of the arbitrary boundaries set by the APA to determine when 
normal behavior ends and abnormal behavior begins. 
 
The prevalence of ADHD increased with the publication of DSM-V. 
However, this increase is most likely due to the comprehensive and 
inclusive nature of the new edition, which captures previously 
undiagnosed patients, rather than to a sudden increase in physician 
over-diagnosis. While studies have shown that a portion of ADHD 
patients disperse their medications to their peers, the focus should be on 
deterring unauthorized use and distribution of these medications rather 
than on the diagnosis of ADHD. 
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LOOKING FORWARD 
Significant research still needs to be done before a better understanding 
of the etiology behind ADHD can emerge. One potential area of research 
includes the role sex has on ADHD. While recent ADHD studies have 
started focusing on girls, the data is still sparse when compared to the 
data available on boys. Part of this is because the hyperactivity-
impulsivity symptoms commonly seen in ADHD boys are more noticeable 
than the inattentive symptoms commonly seen in ADHD girls. This led 
initial researchers to believe that the disorder was one that primarily 
affected boys.  
 
Studies have also pointed to race as yet another factor that may 
influence the presentation of ADHD. For example, the 7R allele of DRD4 
gene that is associated with a high copy number variation is commonly 
found in Caucasians. However, without additional studies, no additional 
light can be shed on what role race plays in ADHD. 
 
While the etiology of ADHD is a complex one that points to a multitude of 
possible contributors, advances in technology have significantly 
narrowed the areas of research. Strides made in research have also led to 
a better understanding of ADHD along with newer forms of treatment. As 
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technology advances and more research is done, researchers will be one 
step closer towards discovering the etiology of ADHD.  
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